Schedule 13D ownership disclosure

CRESCENT BIOPHARMA INC.

Ordinary Shares, par value $0.001 per share · CUSIP: 38000Q201

Event date: 2025-06-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Adage Capital Management, L.P.Reported CIK 0001535978

    Shares: 50,912.00 · Class: 0.37%

  • Robert AtchinsonReported CIK 0001403404

    Shares: 50,912.00 · Class: 0.37%

  • Phillip GrossReported CIK 0001403413

    Shares: 50,912.00 · Class: 0.37%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-002765
Form type
SCHEDULE 13D/A
Filer
Adage Capital Management, L.P.
CIK
CIK 1535978
Filed
Jun 20, 2025
Reporting period
Jun 20, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub